What should be the correct treatment for a 14-year-old child with newly diagnosed Juvenile Rheumatoid Arthritis?

DMARDs with a short course of steroids

DMARDs after initial treatment with NSAIDs

Monotherapy with TNF inhibitors

Long-term high-dose corticosteroid therapy

What is the mechanism of action of Methotrexate?

Inhibition of Dihydrofolate reductase

Inhibits cell replication by acting on G phase of cell cycle

The primary goal of glucocorticoid treatment in rheumatoid arthritis is -

Suppression of inflammation and improvement in functional capacity

Prevention of suppression of the hypothalamic pituitary-adrenal axis

Development of a sense of well-being in the patient

Reversal of the degenerative process

A 50-year-old man presents with complaints of bilateral morning stiffness in his wrists and knees and painful joints on exercise. On physical examination, the joints are slightly swollen. The rest of the examination is unremarkable. His laboratory findings are also negative except for slight anemia, elevated erythrocyte sedimentation rate, and positive rheumatoid factor. The patient was started on weekly methotrexate to control the inflammation. What is the principle mechanism of action here?

Increased extracellular levels of adenosine

Inhibition of assembly of microtubules in neutrophils impairing chemotaxis

Inhibition of cyclooxygenase enzyme

Inhibition of Dihydrofolate reductase enzyme

Pegloticase is used for the treatment of:

Refractory Rheumatoid Arthritis

Drugs Used in Rheumatoid Arthritis for FMGE: High-Yield Pharmacology Lessons

RA & DMARDs Intro - Joint Warfare Kickoff

Rheumatoid Arthritis (RA): Chronic, autoimmune, systemic inflammatory disease targeting synovial joints.
Pathogenesis: Immune attack (T/B cells, Mφ) + cytokines (TNF-α, IL-1, IL-6) → synovitis, pannus, joint destruction.
Goals: Remission/low activity, ↓inflammation/pain, prevent damage, ↑QoL.
DMARDs (Disease-Modifying Antirheumatic Drugs):
- csDMARDs (Conventional Synthetic)
- tsDMARDs (Targeted Synthetic)
- bDMARDs (Biologic)

⭐ Early aggressive treatment with DMARDs is crucial to prevent irreversible joint damage and disability in RA.

csDMARDs - Classic Joint Defenders

⭐ Methotrexate is the anchor csDMARD for RA; co-administration of folic acid (e.g., 5 mg/week) is essential to mitigate its hematologic, GI, and hepatic side effects.

Drug	MoA	Key ADRs (📌 MTX: Myelosuppression, Stomatitis, Liver fibrosis, Pneumonitis)	Contraindications	Monitoring
Methotrexate (MTX)	DHFR inhibitor	Myelosuppression, Stomatitis, Liver fibrosis, Pneumonitis	Pregnancy, liver/renal disease	CBC, LFTs, Scr
Sulfasalazine (SSZ)	Anti-inflam., immunomod.	GI upset, rash, oligospermia, yellow-orange urine	Sulfa allergy, G6PD def.	CBC, LFTs
Leflunomide (LEF)	DHODH inhibitor	Diarrhea, hepatotoxicity, alopecia, HTN	Pregnancy, liver disease	CBC, LFTs, BP
Hydroxychloroquine (HCQ)	TLR inhib., ↑lysosomal pH	Retinopathy, GI upset, rash	Pre-existing maculopathy	Eye exam (baseline, annual >5yrs)

bDMARDs (TNF & IL-6) - Cytokine Storm Tamers

Biological DMARDs (bDMARDs) targeting Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6) are pivotal in Rheumatoid Arthritis (RA) management by downregulating inflammatory cytokine pathways.

Feature	TNF-α Inhibitors	IL-6R Antagonists
Examples	Etanercept, Infliximab, Adalimumab, Golimumab, Certolizumab	Tocilizumab, Sarilumab
Mechanism	Neutralize TNF-α, reducing inflammation.	Block IL-6 receptor, inhibiting IL-6 signaling.
Key ADRs	↑ Infections (esp. TB reactivation), demyelination, injection site reactions.	↑ Infections, dyslipidemia, ↑ LFTs, GI perforation (rare).
Pre-screening	Latent TB, Hepatitis B/C.	Latent TB, Hepatitis B/C, LFTs, lipid profile.

More Biologics & JAKinibs - Precision Joint Ops

Other bDMARDs:
- Abatacept: T-cell co-stimulation modulator. For moderate-severe RA.
- Rituximab: Anti-CD20 B-cell depleter. For TNF-inhibitor refractory RA. ADR: ⚠️ PML.
JAK Inhibitors (tsDMARDs - Oral):
- Tofacitinib, Baricitinib, Upadacitinib.
- MOA: Inhibit Janus Kinase (JAK) enzymes.
- ADRs: Infections (herpes zoster), cytopenias, ↑ lipids.
⭐ JAK inhibitors (e.g., Tofacitinib) are oral targeted DMARDs but carry FDA boxed warnings for increased risk of serious infections, malignancy, major adverse cardiovascular events (MACE), and thrombosis. oka

Adjuncts & Strategy - Relief Crew & Tactics

NSAIDs: Symptomatic relief (pain, inflammation). No disease modification. Key ADRs: GI, renal.
Glucocorticoids: Rapid symptom control (bridging/flares). Bridging: <10mg/day prednisone. ADRs: osteoporosis. Taper ASAP.

⭐ Glucocorticoids are used for rapid symptom control in RA (bridging therapy or flare management) but should be tapered to the lowest effective dose or discontinued as soon as possible due to long-term side effects.
Strategy:
- Treat-to-Target (T2T): Aim remission/Low Disease Activity (LDA).
- Combination DMARDs.
- Monitor disease activity (DAS28).

High‑Yield Points - ⚡ Biggest Takeaways

Methotrexate (MTX) is the anchor DMARD for RA, typically first-line.

Leflunomide inhibits dihydroorotate dehydrogenase; an alternative to MTX.

Sulfasalazine is used for mild RA and IBD; may cause oligospermia.

Hydroxychloroquine (HCQ) is safest DMARD in pregnancy; requires retinal screening.

TNF-α inhibitors (e.g., Infliximab, Adalimumab) increase risk of TB reactivation.

Rituximab, a CD20 inhibitor, depletes B-cells.

Tofacitinib is an oral JAK inhibitor, a newer targeted DMARD.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play